Please select the option that best describes you:
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
How do you view it relative to existing options like TNFi, IL-23, or IL-17s like ixekizumab?
Answer from: at Academic Institution
At this point, I see it as an additional option targeting IL17. This, for many patients, hits the “sweet spot”, with better control of skin disease than TNF inhibitors, and potentially better control of joint disease than IL23 inhibitors, especially for axial disease. My experience with ...
Sign in or Register to read more
Answer from: at Academic Institution
In the absence of head-to-head studies, the following answer is based on my own experience, and not data-driven. Bimekizumab is as good as IL-17A inhibitors (Secukinumab and Ixekizumab) on the skin and musculoskeletal (MSK) domains, better than TNFi on the skin, but equally efficacious on MSK sympto...